Adenovirus vector-derived VA-RNA-mediated innate immune responses

Pharmaceutics

Volumn 3, Issue 3, 2011, Pages 338-353

  Machitani, Mitsuhiro ^a   Yamaguchi, Tomoko ^b   Shimizu, Kahori ^a   Sakurai, Fuminori ^a   Katayama, Kazufumi ^a   Kawabata, Kenji ^a,b   Mizuguchi, Hiroyuki ^a,b  

^a OSAKA UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

Author keywords

Adenovirus vector; Gene therapy; Innate immunity; VA RNA

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; CYTOKINE; GAMMA INTERFERON; INTERFERON GAMMA INDUCED PROTEIN 10; INTERLEUKIN 6; MYELOID DIFFERENTIATION FACTOR 88; RANTES; SMALL UNTRANSLATED RNA; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS ASSOCIATED RNA I; VIRUS ASSOCIATED RNA II;

ADENOVIRUS; ANTIGEN RECOGNITION; COMPLEMENT ACTIVATION; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DENDRITIC CELL; DRUG ADMINISTRATION ROUTE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; GENE TARGETING; HUMAN; INNATE IMMUNITY; KUPFFER CELL; LIVER CELL; NONHUMAN; REVIEW; RNA INTERFERENCE; RNA TRANSCRIPTION; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS EXPRESSION; VIRUS GENOME;

EID: 80053006067     PISSN: None     EISSN: 19994923     Source Type: Journal    
DOI: 10.3390/pharmaceutics3030338     Document Type: Review

References (102)

1. Sakurai, H.; Kawabata, K.; Sakurai, F.; Nakagawa, S.; Mizuguchi, H. Innate immune response induced by gene delivery vectors. Int. J. Pharm. 2008, 354, 9-15.
2. Xu, Z.L.; Mizuguchi, H.; Sakurai, F.; Koizumi, N.; Hosono, T.; Kawabata, K.; Watanabe, Y.; Yamaguchi, T.; Hayakawa, T. Approaches to improving the kinetics of adenovirus-delivered genes and gene products. Adv. Drug Deliv. Rev. 2005, 57, 781-802.
3. Yang, Y.; Ertl, H.C.; Wilson, J.M. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1994, 1, 433-442.
4. Yang, Y.; Li, Q.; Ertl, H.C.; Wilson, J.M. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 1995, 69, 2004-2015.
5. Yang, Y.; Nunes, F.A.; Berencsi, K.; Furth, E.E.; Gönczöl, E.; Wilson, J.M. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA 1994, 91, 4407-4411.
6. Yang, Y.; Ertl, H.C.; Wilson, J.M. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1994, 1, 433-442.
7. Yang, Y.; Xiang, Z.; Ertl, H.C.; Wilson, J.M. Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. Proc. Natl. Acad. Sci. USA 1995, 92, 7257-7261.
8. Gorziglia, M.I.; Kadan, M.J.; Yei, S.; Lim, J.; Lee, G.M.; Luthra, R.; Trapnell, B.C. Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy. J. Virol. 1996, 70, 4173-4178.
9. Gao, G.P.; Yang, Y.; Wilson, J.M. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J. Virol. 1996, 70, 8934-8943.
10. Lusky, M.; Christ, M.; Rittner, K.; Dieterle, A.; Dreyer, D.; Mourot, B.; Schultz, H.; Stoeckel, F.; Pavirani, A.; Mehtali, M. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J. Virol. 1998, 72, 2022-2032.
11. Sharma, A.; Bangari, D.S.; Tandon, M.; Pandey, A.; HogenEsch, H.; Mittal, S.K. Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model. Virology 2009, 386, 44-54.
12. Wang, Q.; Finer, M.H. Second-generation adenovirus vectors. Nat. Med. 1996, 2, 714-716.
13. Chen, D.; Murphy, B.; Sung, R.; Bromberg, J.S. Adaptive and innate immune responses to gene transfer vectors: role of cytokines and chemokines in vector function. Gene Therapy 2003, 10, 991-998.
14. Shimizu, K.; Sakurai, F.; Machitani, M.; Katayama, K.; Mizuguchi, H. Quantitative analysis of the leaky expression of adenovirus genes in cells transduced with a replication-incompetent adenovirus vector. Mol. Pharm. 2011, In Press.
15. Palmer, D.J.; Ng, P. Helper-dependent adenoviral vectors for gene therapy. Hum. Gene Ther. 2005, 16, 1-16.
16. Roberts, D.M.; Nanda, A.; Havenga, M.J.; Abbink, P.; Lynch, D.M.; Ewald, B.A.; Liu, J.; Thorner, A.R.; Swanson, P.E.; Gorgone, D.A., et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 2006, 441, 239-243.
17. Farina, S.F.; Gao, G.P.; Xiang, Z.Q.; Rux, J.J.; Burnett, R.M.; Alvira, M.R.; Marsh, J.; Ertl, H.C.; Wilson, J.M. Replication-defective vector based on a chimpanzee adenovirus. J. Virol. 2001, 75, 11603-11613.
18. Sakurai, F.; Mizuguchi, H.; Hayakawa, T. Efficient gene transfer into human CD34+ cells by an adenovirus type 35 vector. Gene Therapy 2003, 10, 1041-1048.
19. Vogels, R.; Zuijdgeest, D.; van Rijnsoever, R.; Hartkoorn, E.; Damen, I.; de Bethune, M.P.; Kostense, S.; Penders, G.; Helmus, N.; Koudstaal, W., et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J. Virol. 2003, 77, 8263-8271.
20. Holterman, L.; Vogels, R.; van der Vlugt, R.; Sieuwerts, M.; Grimbergen, J.; Kaspers, J.; Geelen, E.; van der Helm, E.; Lemckert, A.; Gillissen, G., et al. Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5. J. Virol. 2004, 78, 13207-13215.
21. Seshidhar Reddy, P.; Ganesh, S.; Limbach, M.P.; Brann, T.; Pinkstaff, A.; Kaloss, M.; Kaleko, M.; Connelly, S. Development of adenovirus serotype 35 as a gene transfer vector. Virology 2003, 311, 384-393.
22. Muruve, D.A.; Cotter, M.J.; Zaiss, A.K.; White, L.R.; Liu, Q.; Chan, T.; Clark, S.A.; Ross, P.J.; Meulenbroek, R.A.; Maelandsmo, G.M., et al. Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. J. Virol. 2004, 78, 5966-5972.
23. Yamaguchi, T.; Kawabata, K.; Kouyama, E.; Ishii, K.J.; Katayama, K.; Suzuki, T.; Kurachi, S.; Sakurai, F.; Akira, S.; Mizuguchi, H. Induction of type I interferon by adenovirus-encoded small RNAs. Proc. Natl. Acad. Sci. USA 2010, 107, 17286-17291.
24. Yamaguchi, T.; Kawabata, K.; Koizumi, N.; Sakurai, F.; Nakashima, K.; Sakurai, H.; Sasaki, T.; Okada, N.; Yamanishi, K.; Mizuguchi, H. Role of MyD88 and TLR9 in the innate immune response elicited by serotype 5 adenoviral vectors. Hum. Gene Ther. 2007, 18, 753-762.
25. Minamitani, T.; Iwakiri, D.; Takada, K. Adenovirus virus-associated RNAs induce type I interferon expression through a RIG-I-mediated pathway. J. Virol. 2011, 85, 4035-4040.
26. Alemany, R.; Suzuki, K.; Curiel, D.T. Blood clearance rates of adenovirus type 5 in mice. J. Gen. Virol. 2000, 81, 2605-2609.
27. Koizumi, N.; Mizuguchi, H.; Sakurai, F.; Yamaguchi, T.; Watanabe, Y.; Hayakawa, T. Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR- and alphav integrin-binding ablation. J. Virol. 2003, 77, 13062-13072.
28. Sakurai, F.; Mizuguchi, H.; Yamaguchi, T.; Hayakawa, T. Characterization of in vitro and in vivo gene transfer properties of adenovirus serotype 35 vector. Mol. Ther. 2003, 8, 813-821.
29. Lieber, A.; He, C.Y.; Meuse, L.; Schowalter, D.; Kirillova, I.; Winther, B.; Kay, M.A. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J. Virol. 1997, 71, 8798-8807.
30. Wolff, G.; Worgall, S.; van Rooijen, N.; Song, W.R.; Harvey, B.G.; Crystal, R.G. Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. J. Virol. 1997, 71, 624-629.
31. Worgall, S.; Wolff, G.; Falck-Pedersen, E.; Crystal, R.G. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum. Gene Ther. 1997, 8, 37-44.
32. Tao, N.; Gao, G.P.; Parr, M.; Johnston, J.; Baradet, T.; Wilson, J.M.; Barsoum, J.; Fawell, S.E. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol. Ther. 2001, 3, 28-35.
33. Koizumi, N.; Kawabata, K.; Sakurai, F.; Watanabe, Y.; Hayakawa, T.; Mizuguchi, H. Modified adenoviral vectors ablated for coxsackievirus-adenovirus receptor, alphav integrin, and heparan sulfate binding reduce in vivo tissue transduction and toxicity. Hum. Gene Ther. 2006, 17, 264-279.
34. Liu, Q.; Muruve, D.A. Molecular basis of the inflammatory response to adenovirus vectors. Gene Therapy 2003, 10, 935-940.
35. Zhang, Y.; Chirmule, N.; Gao, G.P.; Qian, R.; Croyle, M.; Joshi, B.; Tazelaar, J.; Wilson, J.M. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol. Ther. 2001, 3, 697-707.
36. De Geest, B.; Snoeys, J.; Van Linthout, S.; Lievens, J.; Collen, D. Elimination of innate immune responses and liver inflammation by PEGylation of adenoviral vectors and methylprednisolone. Hum. Gene Ther. 2005, 16, 1439-1451.
37. Koizumi, N.; Yamaguchi, T.; Kawabata, K.; Sakurai, F.; Sasaki, T.; Watanabe, Y.; Hayakawa, T.; Mizuguchi, H. Fiber-modified adenovirus vectors decrease liver toxicity through reduced interleukin 6 production. J. Immunol. 2007, 178, 1767-1773.
38. Kiang, A.; Hartman, Z.C.; Everett, R.S.; Serra, D.; Jiang, H.; Frank, M.M.; Amalfitano, A. Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system. Mol. Ther. 2006, 14, 588-598.
39. Tian, J.; Xu, Z.; Smith, J.S.; Hofherr, S.E.; Barry, M.A.; Byrnes, A.P. Adenovirus activates complement by distinctly different mechanisms in vitro and in vivo: indirect complement activation by virions in vivo. J. Virol. 2009, 83, 5648-5658.
40. Xu, Z.; Tian, J.; Smith, J.S.; Byrnes, A.P. Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. J. Virol. 2008, 82, 11705-11713.
41. Parker, A.L.; Waddington, S.N.; Nicol, C.G.; Shayakhmetov, D.M.; Buckley, S.M.; Denby, L.; Kemball-Cook, G.; Ni, S.; Lieber, A.; McVey, J.H., et al. Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood 2006, 108, 2554-2561.
42. Shayakhmetov, D.M.; Gaggar, A.; Ni, S.; Li, Z.Y.; Lieber, A. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J. Virol. 2005, 79, 7478-7491.
43. Waddington, S.N.; McVey, J.H.; Bhella, D.; Parker, A.L.; Barker, K.; Atoda, H.; Pink, R.; Buckley, S.M.; Greig, J.A.; Denby, L., et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008, 132, 397-409.
44. Parker, A.L.; Waddington, S.N.; Buckley, S.M.; Custers, J.; Havenga, M.J.; van Rooijen, N.; Goudsmit, J.; McVey, J.H.; Nicklin, S.A.; Baker, A.H. Effect of neutralizing sera on factor x-mediated adenovirus serotype 5 gene transfer. J. Virol. 2009, 83, 479-483.
45. Kalyuzhniy, O.; Di Paolo, N.C.; Silvestry, M.; Hofherr, S.E.; Barry, M.A.; Stewart, P.L.; Shayakhmetov, D.M. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc. Natl. Acad. Sci. USA 2008, 105, 5483-5488.
46. Prill, J.M.; Espenlaub, S.; Samen, U.; Engler, T.; Schmidt, E.; Vetrini, F.; Rosewell, A.; Grove, N.; Palmer, D.; Ng, P., et al. Modifications of adenovirus hexon allow for either hepatocyte detargeting or targeting with potential evasion from Kupffer cells. Mol. Ther. 2011, 19, 83-92.
47. Yoneyama, M.; Fujita, T. Recognition of viral nucleic acids in innate immunity. Rev. Med. Virol. 2010, 20, 4-22.
48. Basner-Tschakarjan, E.; Gaffal, E.; O'Keeffe, M.; Tormo, D.; Limmer, A.; Wagner, H.; Hochrein, H.; Tuting, T. Adenovirus efficiently transduces plasmacytoid dendritic cells resulting in TLR9-dependent maturation and IFN-alpha production. J. Gene Med. 2006, 8, 1300-1306.
49. Zhu, J.; Huang, X.; Yang, Y. Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. J. Virol. 2007, 81, 3170-3180.
50. Yoneyama, M.; Kikuchi, M.; Natsukawa, T.; Shinobu, N.; Imaizumi, T.; Miyagishi, M.; Taira, K.; Akira, S.; Fujita, T. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 2004, 5, 730-737.
51. Yoneyama, M.; Kikuchi, M.; Matsumoto, K.; Imaizumi, T.; Miyagishi, M.; Taira, K.; Foy, E.; Loo, Y.M.; Gale, M., Jr.; Akira, S., et al. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J. Immunol. 2005, 175, 2851-2858.
52. Andrejeva, J.; Childs, K.S.; Young, D.F.; Carlos, T.S.; Stock, N.; Goodbourn, S.; Randall, R.E. The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter. Proc. Natl. Acad. Sci. USA 2004, 101, 17264-17269.
53. Kato, H.; Takeuchi, O.; Sato, S.; Yoneyama, M.; Yamamoto, M.; Matsui, K.; Uematsu, S.; Jung, A.; Kawai, T.; Ishii, K.J., et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006, 441, 101-105.
54. Kato, H.; Sato, S.; Yoneyama, M.; Yamamoto, M.; Uematsu, S.; Matsui, K.; Tsujimura, T.; Takeda, K.; Fujita, T.; Takeuchi, O., et al. Cell type-specific involvement of RIG-I in antiviral response. Immunity 2005, 23, 19-28.
55. Hornung, V.; Ellegast, J.; Kim, S.; Brzozka, K.; Jung, A.; Kato, H.; Poeck, H.; Akira, S.; Conzelmann, K.K.; Schlee, M., et al. 5'-Triphosphate RNA is the ligand for RIG-I. Science 2006, 314, 994-997.
56. Cui, S.; Eisenacher, K.; Kirchhofer, A.; Brzozka, K.; Lammens, A.; Lammens, K.; Fujita, T.; Conzelmann, K.K.; Krug, A.; Hopfner, K.P. The C-terminal regulatory domain is the RNA 5'-triphosphate sensor of RIG-I. Mol. Cell 2008, 29, 169-179.
57. Nallagatla, S.R.; Hwang, J.; Toroney, R.; Zheng, X.; Cameron, C.E.; Bevilacqua, P.C. 5'-triphosphate-dependent activation of PKR by RNAs with short stem-loops. Science 2007, 318, 1455-1458.
58. Kawai, T.; Takahashi, K.; Sato, S.; Coban, C.; Kumar, H.; Kato, H.; Ishii, K.J.; Takeuchi, O.; Akira, S. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat. Immunol. 2005, 6, 981-988.
59. Mathews, M.B.; Shenk, T. Adenovirus virus-associated RNA and translation control. J. Virol. 1991, 65, 5657-5662.
60. Fowlkes, D.M.; Shenk, T. Transcriptional control regions of the adenovirus VAI RNA gene. Cell 1980, 22, 405-413.
61. Bhat, R.A.; Metz, B.; Thimmappaya, B. Organization of the noncontiguous promoter components of adenovirus VAI RNA gene is strikingly similar to that of eucaryotic tRNA genes. Mol. Cell. Biol. 1983, 3, 1996-2005.
62. Akusjarvi, G.; Mathews, M.B.; Andersson, P.; Vennstrom, B.; Pettersson, U. Structure of genes for virus-associated RNAI and RNAII of adenovirus type 2. Proc. Natl. Acad. Sci. USA 1980, 77, 2424-2428.
63. Ma, Y.; Mathews, M.B. Structure, function, and evolution of adenovirus-associated RNA: a phylogenetic approach. J. Virol. 1996, 70, 5083-5099.
64. Clarke, P.A.; Pe'ery, T.; Ma, Y.; Mathews, M.B. Structural features of adenovirus 2 virus-associated RNA required for binding to the protein kinase DAI. Nucleic Acids Res. 1994, 22, 4364-4374.
65. Ghadge, G.D.; Swaminathan, S.; Katze, M.G.; Thimmapaya, B. Binding of the adenovirus VAI RNA to the interferon-induced 68-kDa protein kinase correlates with function. Proc. Natl. Acad. Sci. USA 1991, 88, 7140-7144.
66. Mellits, K.H.; Pe'ery, T.; Mathews, M.B. Role of the apical stem in maintaining the structure and function of adenovirus virus-associated RNA. J. Virol. 1992, 66, 2369-2377.
67. Mellits, K.H.; Kostura, M.; Mathews, M.B. Interaction of adenovirus VA RNAl with the protein kinase DAI: nonequivalence of binding and function. Cell 1990, 61, 843-852.
68. Mellits, K.H.; Mathews, M.B. Effects of mutations in stem and loop regions on the structure and function of adenovirus VA RNAI. Embo J. 1988, 7, 2849-2859.
69. Ghadge, G.D.; Malhotra, P.; Furtado, M.R.; Dhar, R.; Thimmapaya, B. In vitro analysis of virus-associated RNA I (VAI RNA): inhibition of the double-stranded RNA-activated protein kinase PKR by VAI RNA mutants correlates with the in vivo phenotype and the structural integrity of the central domain. J. Virol. 1994, 68, 4137-4151.
70. Pe'ery, T.; Mellits, K.H.; Mathews, M.B. Mutational analysis of the central domain of adenovirus virus-associated RNA mandates a revision of the proposed secondary structure. J. Virol. 1993, 67, 3534-3543.
71. Rahman, A.; Malhotra, P.; Dhar, R.; Kewalramani, T.; Thimmapaya, B. Effect of single-base substitutions in the central domain of virus-associated RNA I on its function. J. Virol. 1995, 69, 4299-4307.
72. Gwizdek, C.; Ossareh-Nazari, B.; Brownawell, A.M.; Doglio, A.; Bertrand, E.; Macara, I.G.; Dargemont, C. Exportin-5 mediates nuclear export of minihelix-containing RNAs. J. Biol. Chem. 2003, 278, 5505-5508.
73. Subramanian, S.; Bhat, R.A.; Rundell, M.K.; Thimmappaya, B. Suppression of the translation defect phenotype specific for a virus-associated RNA-deficient adenovirus mutant in monkey cells by simian virus 40. J. Virol. 1986, 60, 363-368.
74. Thimmappaya, B.; Weinberger, C.; Schneider, R.J.; Shenk, T. Adenovirus VAI RNA is required for efficient translation of viral mRNAs at late times after infection. Cell 1982, 31, 543-551.
75. Aparicio, O.; Razquin, N.; Zaratiegui, M.; Narvaiza, I.; Fortes, P. Adenovirus virus-associated RNA is processed to functional interfering RNAs involved in virus production. J. Virol. 2006, 80, 1376-1384.
76. Bhat, R.A.; Thimmappaya, B. Adenovirus mutants with DNA sequence perturbations in the intragenic promoter of VAI RNA gene allow the enhanced transcription of VAII RNA gene in HeLa cells. Nucleic Acids Res. 1984, 12, 7377-7388.
77. Kitajewski, J.; Schneider, R.J.; Safer, B.; Munemitsu, S.M.; Samuel, C.E.; Thimmappaya, B.; Shenk, T. Adenovirus VAI RNA antagonizes the antiviral action of interferon by preventing activation of the interferon-induced eIF-2 alpha kinase. Cell 1986, 45, 195-200.
78. Garcia, M.A.; Gil, J.; Ventoso, I.; Guerra, S.; Domingo, E.; Rivas, C.; Esteban, M. Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. Microbiol. Mol. Biol. Rev. 2006, 70, 1032-1060.
79. Krishnamoorthy, T.; Pavitt, G.D.; Zhang, F.; Dever, T.E.; Hinnebusch, A.G. Tight binding of the phosphorylated alpha subunit of initiation factor 2 (eIF2alpha) to the regulatory subunits of guanine nucleotide exchange factor eIF2B is required for inhibition of translation initiation. Mol. Cell. Biol. 2001, 21, 5018-5030.
80. Nallagatla, S.R.; Toroney, R.; Bevilacqua, P.C. Regulation of innate immunity through RNA structure and the protein kinase PKR. Curr. Opin. Struct. Biol. 2011, 21, 119-127.
81. Pathak, V.K.; Schindler, D.; Hershey, J.W. Generation of a mutant form of protein synthesis initiation factor eIF-2 lacking the site of phosphorylation by eIF-2 kinases. Mol. Cell. Biol. 1988, 8, 993-995.
82. Rowlands, A.G.; Panniers, R.; Henshaw, E.C. The catalytic mechanism of guanine nucleotide exchange factor action and competitive inhibition by phosphorylated eukaryotic initiation factor 2. J. Biol. Chem. 1988, 263, 5526-5533.
83. O'Malley, R.P.; Mariano, T.M.; Siekierka, J.; Mathews, M.B. A mechanism for the control of protein synthesis by adenovirus VA RNAI. Cell 1986, 44, 391-400.
84. Wahid, A.M.; Coventry, V.K.; Conn, G.L. Systematic deletion of the adenovirus-associated RNAI terminal stem reveals a surprisingly active RNA inhibitor of double-stranded RNA-activated protein kinase. J. Biol. Chem. 2008, 283, 17485-17493.
85. Coventry, V.K.; Conn, G.L. Analysis of adenovirus VA RNAI structure and stability using compensatory base pair modifications. Nucleic Acids Res. 2008, 36, 1645-1653.
86. Ma, Y.; Mathews, M.B. Comparative analysis of the structure and function of adenovirus virus-associated RNAs. J. Virol. 1993, 67, 6605-6617.
87. Sano, M.; Kato, Y.; Taira, K. Sequence-specific interference by small RNAs derived from adenovirus VAI RNA. FEBS Lett. 2006, 580, 1553-1564.
88. Lu, S.; Cullen, B.R. Adenovirus VA1 noncoding RNA can inhibit small interfering RNA and MicroRNA biogenesis. J. Virol. 2004, 78, 12868-12876.
89. Xu, N.; Segerman, B.; Zhou, X.; Akusjarvi, G. Adenovirus virus-associated RNAII-derived small RNAs are efficiently incorporated into the rna-induced silencing complex and associate with polyribosomes. J. Virol. 2007, 81, 10540-10549.
90. Andersson, M.G.; Haasnoot, P.C.; Xu, N.; Berenjian, S.; Berkhout, B.; Akusjarvi, G. Suppression of RNA interference by adenovirus virus-associated RNA. J. Virol. 2005, 79, 9556-9565.
91. Aparicio, O.; Carnero, E.; Abad, X.; Razquin, N.; Guruceaga, E.; Segura, V.; Fortes, P. Adenovirus VA RNA-derived miRNAs target cellular genes involved in cell growth, gene expression and DNA repair. Nucleic Acids Res. 2010, 38, 750-763.
92. Xu, N.; Gkountela, S.; Saeed, K.; Akusjarvi, G. The 5'-end heterogeneity of adenovirus virus-associated RNAI contributes to the asymmetric guide strand incorporation into the RNA-induced silencing complex. Nucleic Acids Res. 2009, 37, 6950-6959.
93. Thimmappaya, B.; Jones, N.; Shenk, T. A mutation which alters initiation of transcription by RNA polymerase III on the Ad5 chromosome. Cell 1979, 18, 947-954.
94. Vennstrom, B.; Pettersson, U.; Philipson, L. Two initiation sites for adenovirus 5.5S RNA. Nucleic Acids Res. 1978, 5, 195-204.
95. Skalsky, R.L.; Cullen, B.R. Viruses, microRNAs, and host interactions. Annu. Rev. Microbiol. 2010, 64, 123-41.
96. Cullen, B.R. Viral RNAs: lessons from the enemy. Cell 2009, 136, 592-597.
97. Samanta, M.; Iwakiri, D.; Kanda, T.; Imaizumi, T.; Takada, K. EB virus-encoded RNAs are recognized by RIG-I and activate signaling to induce type I IFN. Embo J. 2006, 25, 4207-4214.
98. Iwakiri, D.; Zhou, L.; Samanta, M.; Matsumoto, M.; Ebihara, T.; Seya, T.; Imai, S.; Fujieda, M.; Kawa, K.; Takada, K. Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from Toll-like receptor 3. J. Exp. Med. 2009, 206, 2091-2099.
99. Pichlmair, A.; Schulz, O.; Tan, C.P.; Naslund, T.I.; Liljestrom, P.; Weber, F.; Reis e Sousa, C. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. Science 2006, 314, 997-1001.
100. Rajan, P.; Swaminathan, S.; Zhu, J.; Cole, C.N.; Barber, G.; Tevethia, M.J.; Thimmapaya, B. A novel translational regulation function for the simian virus 40 large-T antigen gene. J. Virol. 1995, 69, 785-795.
101. Cascalló, M.; Capellà, G.; Mazo, A.; Alemany, R. Ras-dependent oncolysis with an adenovirus VAI mutant. Cancer Res. 2003, 63, 5544-5550.
102. Machitani, M.; Katayama, K.; Sakurai, F.; Matsui, H.; Yamaguchi, T.; Suzuki, T.; Miyoshi, H.; Kawabata, K.; Mizuguchi, H. Development of an adenovirus vector lacking the expression of virus-associated RNAs. J. Control. Release 2011, In Press.